Compounds > 9-aminocamptothecin
Page last updated: 2024-08-25

9-aminocamptothecin and Brain Neoplasms

9-aminocamptothecin has been researched along with Brain Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (66.67)18.2507
2000's2 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ahluwalia, MS; Barnett, GH; Cohen, BH; Farray, D; Peereboom, DM; Snyder, J; Suh, JH1
Friedman, HS; Houghton, PJ1
Fisher, JD; Grossman, S; Piantadosi, S1
Chen, TL; Fisher, J; Gregory, R; Grochow, LB; Grossman, SA; Hochberg, F; Kim, L; Piantadosi, S1
Lad, TE; Minami, H; Nicholas, MK; Ratain, MJ; Vokes, EE1
Fisher, JD; Glantz, M; Grossman, SA; Hochberg, F; Mikkelsen, T; Piantadosi, S1

Trials

3 trial(s) available for 9-aminocamptothecin and Brain Neoplasms

ArticleYear
Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme.
    Investigational new drugs, 2006, Volume: 24, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Treatment Outcome

2006
Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:2

    Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Drug Interactions; Glioblastoma; Humans; Middle Aged

1998
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:6

    Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Glioma; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Logistic Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged

1999

Other Studies

3 other study(ies) available for 9-aminocamptothecin and Brain Neoplasms

ArticleYear
Treatment of central nervous system xenografts with camptothecins.
    Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803

    Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Topotecan; Transplantation, Heterologous

1996
Practical implementation of a modified continual reassessment method for dose-finding trials.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:6

    Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Glioblastoma; Humans; Models, Theoretical; Neoplasm Recurrence, Local; Reproducibility of Results

1998
Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma. NABTT CNS Consortium.
    Neuro-oncology, 2000, Volume: 2, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Treatment Failure

2000